Johnson & Johnson (NYSE: JNJ) today announced pivotal results from the Phase 1b/2 OrigAMI-4 study showing that subcutaneous amivantamab and hyaluronidase-lpuj delivered durable responses in patients ...

CHICAGO, May 31, 2026 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ) today announced pivotal results from the Phase 1b/2 OrigAMI-4 study showing that subcutaneous amivantamab and hyaluronidase-lpuj ...

On May 12, 2026, the Patent Trial and Appeal Board (“PTAB”) issued a Final Written Decision (“FWD”) in PGR2025-00003 finding all challenged claims of Halozyme’s U.S. Patent No. 11,952,600 (“the ’600 ...

The U.S. Food and Drug Administration has approved a label expansion for Vyvgart (efgartigimod alfa-fcab) and Vyvgart Hytrulo (efgartigimod alfa and hyaluronidase-qvfc) for the treatment of adult ...

Readouts in rare blood cancers like myelofibrosis, WM and CLL are attracting keen interest at this year’s ASCO conference.

We recently compiled a list of the 8 Best Immunology Stocks to Buy According to Hedge Funds. Takeda Pharmaceutical Company ...

Teclistamab improved PFS, OS in patients who had received up to three previous lines of th ...

ALKIVIA+ data in myositis indicate efgartigimod provides sustained, clinically meaningful improvements and consistent safety RHO+ data in ...

Vyvgart first gained approval by the FDA for generalised myasthenia gravis (gMG) in 2021.

Bristol Myers secured EU approval for Opdivo plus AVD in newly diagnosed advanced cHL and advanced Camzyos' label expansion ...

J&J’s amivantamab (Rybrevant Faspro) shows a 42% response rate in advanced head & neck cancer, boosting FDA approval odds—see ...

Three out of four new biologic approvals are now device-based pens, prefilled syringes, autoinjectors, and increasingly ...